Atgam or Lymphocyte immunoglobulin antithymocyte is an injection manufactured by Pfizer. It is used for the prevention and treatment of acute renal allograft rejection among other ailments. We are a trusted Atgam 250mg Exporter and Supplier in Maharashtra (India). We make them available in proper and safe packaging and at highly affordable rates.
Atgam 250mg injection is used for :
Prevention and treatment of acute renal allograft rejection
Prevention of graft-vs-host disease (GVHD) in bone marrow transplant (BMT) patients
Treatment of aplastic anemia in patients not suitable for BMT
Dose and Administration : A test dose (0.1 mL of a freshly prepared 0.05 mg/mL solution in NS) may be given intradermally. The patient and injection site is examined every 15 min for one hr. However, a negative test does not guarantee a reaction-free administration. Also, a positive reaction does not always mean that the drug cannont be used with extreme caution if it is absolutely essential (risk/benefit analysis is necessary).
Before each dose, the patient may be pretreated with diphenhydramine (Benadryl) and acetaminophen (Tylenol). The ATGAM dose must be diluted in normal saline or 1/2 normal saline to a concentration not exceeding 4 mg/mL. If the drug is to be given via a peripheral line (not recommended) the concentration should be less than 1 mg/mL.
The ATGAM dose should be administered via iv infusion into a central line over a minimum of 4 – 8 hrs. Infusion should be stopped immediately if a systemic reaction (dyspnea, tachycardia, hypotension, or a generalized skin reaction) or anaphylaxis occurs. Acute Renal Allograft Rejection: 15 mg / kg q24h for 14 days, then give q48h for 7 more doses for a total of 21 doses in 28 days. Therapy should be discontinued if severe thrombocytopenia or leukopenia occurs.
Aplastic Anemia: 15 mg / kg q24h for 10 days, then give q48h for 7 more doses. Another protocol which is used only in adults calls simply for 40 mg/kg q24h for 4 days.
Drug Interactions : No pharmacokinetic drug interactions have been described. Excessive immunosuppression can occur when used in combination with other immunosuppressive agents.